Reducing neonatal morbidity by discontinuing oxytocin during the active phase of first stage of labor: a multicenter randomized controlled trial STOPOXY

Aude Girault, François Goffinet, Camille Le Ray, collaborators of the STOPOXY trial and the Groupe de Recherche en Obstétrique et Gynécologie (GROG), Elie Azria, Tiphaine Barjat, Charline Bertholdt, Julie Blanc, Caroline Bohec, Eric Boudier, Julie Carrara, Raoul Desbriere, Muriel Doret, Charles Garabedian, Hélène Heckenroth, Gilles Kayem, Diane Korb, Gilles Levy, Georges-Emmanuel Roth, Patrick Rozenberg, Loïc Sentilhes, Eric Verspyck, Norbert Winer, Aude Girault, François Goffinet, Camille Le Ray, collaborators of the STOPOXY trial and the Groupe de Recherche en Obstétrique et Gynécologie (GROG), Elie Azria, Tiphaine Barjat, Charline Bertholdt, Julie Blanc, Caroline Bohec, Eric Boudier, Julie Carrara, Raoul Desbriere, Muriel Doret, Charles Garabedian, Hélène Heckenroth, Gilles Kayem, Diane Korb, Gilles Levy, Georges-Emmanuel Roth, Patrick Rozenberg, Loïc Sentilhes, Eric Verspyck, Norbert Winer

Abstract

Background: Oxytocin is effective in reducing labor duration, but can be associated with fetal and maternal complications such as neonatal acidosis and post-partum hemorrhage. When comparing discontinuing oxytocin in the active phase with continuing oxytocin infusion, previous studies were underpowered to show a reduction in neonatal morbidity. Thus, we aim at evaluating the impact of discontinuing oxytocin during the active phase of the first stage of labor on the neonatal morbidity rate.

Methods: STOPOXY is a multicenter, randomized, open-label, controlled trial conducted in 20 maternity units in France. The first participant was recruited January 17th 2020. The trial includes women with a live term (≥37 weeks) singleton, in cephalic presentation, receiving oxytocin before 4 cm, after an induced or spontaneous labor. Women aged < 18 years, with a lack of social security coverage, a scarred uterus, a multiple pregnancy, a fetal congenital malformation, a growth retardation <3rd percentile or an abnormal fetal heart rate at randomization are excluded. Women are randomized before 6 cm when oxytocin is either continued or discontinued. Randomization is stratified by center and parity. The primary outcome, neonatal morbidity is assessed using a composite variable defined by an umbilical arterial pH at birth < 7.10 and/or a base excess > 10 mmol/L and/or umbilical arterial lactates> 7 mmol/L and/or a 5 min Apgar score < 7 and/or admission in neonatal intensive care unit. The primary outcome will be compared between the two groups using a chi-square test with a p-value of 0.05. Secondary outcomes include neonatal complications, duration of active phase, mode of delivery, fetal and maternal complications during labor and delivery, including cesarean delivery rate and postpartum hemorrhage, and birth experience. We aim at including 2475 women based on a reduction in neonatal morbidity from 8% in the control group to 5% in the experimental group, with a power of 80% and an alpha risk of 5%.

Discussion: Discontinuing oxytocin during the active phase of labor could improve both child health, by reducing moderate to severe neonatal morbidity, and maternal health by reducing cesarean delivery and postpartum hemorrhage rates.

Trial registration: Clinical trials NCT03991091 , registered June 19th, 2019.

Keywords: Birth experience; Cesarean delivery; Discontinuation; Labor duration; Neonatal morbidity; Oxytocin.

Conflict of interest statement

None.

References

    1. Blondel B, Coulm B, Bonnet C, Goffinet F, Le Ray C, National Coordination Group of the National Perinatal Surveys Trends in perinatal health in metropolitan France from 1995 to 2016: results from the French National Perinatal Surveys. J Gynecol Obstet Hum Reprod. 2017;46:701–713. doi: 10.1016/j.jogoh.2017.09.002.
    1. O’Driscoll K, Jackson RJ, Gallagher JT. Prevention of prolonged labour. Br Med J. 1969;2:477–480. doi: 10.1136/bmj.2.5655.477.
    1. Nachum Z, Garmi G, Kadan Y, Zafran N, Shalev E, Salim R. Comparison between amniotomy, oxytocin or both for augmentation of labor in prolonged latent phase: a randomized controlled trial. Reprod Biol Endocrinol. 2010;8:136. doi: 10.1186/1477-7827-8-136.
    1. Crane JM, Young DC, Butt KD, Bennett KA, Hutchens D. Excessive uterine activity accompanying induced labor. Obstet Gynecol. 2001;97:926–931.
    1. Simpson KR, James DC. Effects of oxytocin-induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. Am J Obstet Gynecol. 2008;199:34.e1–34.e5. doi: 10.1016/j.ajog.2007.12.015.
    1. Brown HC, Paranjothy S, Dowswell T, Thomas J. Package of care for active management in labour for reducing caesarean section rates in low-risk women. Cochrane Database Syst Rev. 2013:CD004907. 10.1002/14651858.CD004907.pub3.
    1. Glantz JC, McNanley TJ. Active management of labor: a meta-analysis of cesarean delivery rates for dystocia in nulliparas. Obstet Gynecol Surv. 1997;52:497–505. doi: 10.1097/00006254-199708000-00021.
    1. Belghiti J, Kayem G, Dupont C, Rudigoz R-C, Bouvier-Colle M-H, Deneux-Tharaux C. Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study. BMJ Open. 2011;1:e000514. doi: 10.1136/bmjopen-2011-000514.
    1. Dupont C, Carayol M, Le Ray C, Deneux-Tharaux C, Riethmuller D, Clinical practice guidelines group Oxytocin administration during spontaneous labor: guidelines for clinical practice. Guidelines short text. J Gynecol Obstet Hum Reprod. 2017;46:539–543. doi: 10.1016/j.jogoh.2017.04.010.
    1. American College of Obstetrics and Gynecology Committee on Practice Bulletins-Obstetrics ACOG practice bulletin number 49, December 2003: dystocia and augmentation of labor. Obstet Gynecol. 2003;102:1445–1454.
    1. WHO . Recommendations for augmentation of labour. Geneva: World Health Organization; 2014.
    1. Saccone G, Ciardulli A, Baxter JK, Quiñones JN, Diven LC, Pinar B, et al. Discontinuing oxytocin infusion in the active phase of labor: a systematic review and meta-analysis. Obstet Gynecol. 2017;130:1090–1096. doi: 10.1097/AOG.0000000000002325.
    1. Daniel-Spiegel E, Weiner Z, Ben-Shlomo I, Shalev E. For how long should oxytocin be continued during induction of labour? BJOG. 2004;111:331–334. doi: 10.1111/j.1471-0528.2004.00096.x.
    1. Bor P, Ledertoug S, Boie S, Knoblauch NO, Stornes I. Continuation versus discontinuation of oxytocin infusion during the active phase of labour: a randomised controlled trial. BJOG. 2016;123:129–135. doi: 10.1111/1471-0528.13589.
    1. Girard B, Vardon D, Creveuil C, Herlicoviez M, Dreyfus M. Discontinuation of oxytocin in the active phase of labor. Acta Obstet Gynecol Scand. 2009;88:172–177. doi: 10.1080/00016340802649816.
    1. Ustunyurt E, Ugur M, Ustunyurt BO, Iskender TC, Ozkan O, Mollamahmutoglu L. Prospective randomized study of oxytocin discontinuation after the active stage of labor is established. J Obstet Gynaecol Res. 2007;33:799–803. doi: 10.1111/j.1447-0756.2007.00659.x.
    1. Chopra S, SenGupta SK, Jain V, Kumar P. Stopping oxytocin in active labor rather than continuing it until delivery: a viable option for the induction of labor. Oman Med J. 2015;30:320–325. doi: 10.5001/omj.2015.66.
    1. Diven LC, Rochon ML, Gogle J, Eid S, Smulian JC, Quiñones JN. Oxytocin discontinuation during active labor in women who undergo labor induction. Am J Obstet Gynecol. 2012;207:471.e1–471.e8. doi: 10.1016/j.ajog.2012.08.035.
    1. Blanc-Petitjean P, Salomé M, Dupont C, Crenn-Hebert C, Gaudineau A, Perrotte F, et al. Labour induction practices in France: a population-based declarative survey in 94 maternity units. J Gynecol Obstet Hum Reprod. 2018;47:57–62. doi: 10.1016/j.jogoh.2017.11.006.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi